Tetra Radar · FDA Approvals · Decision date
gedatolisib: FDA decision date
Faeth Therapeutics Inc. (FTH) · 17 July 2026
Gedatolisib , an IV pan-PI3K/mTOR inhibitor from Celcuity, whose New Drug Application for HR+/HER2, PIK3CA wild-type metastatic breast cancer was accepted by the FDA in January 2026 with Priority Review and a Prescription Drug User Fee Act goal date of July 17, 2026.
Source: 10-K/A of 2 June 2026
The date has passed; Tetra Radar has not recorded an approval.
Faeth Therapeutics Inc. on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.